23C6 / TellBio - LARVOL DELTA

Reduction in Circulating Tumor Cells (CTC), Enriched by TellBio Platform, with Novel Dual-Cadherin Antibody (23C6) Results in Significant Metastasis Suppression (GlobeNewswire) - "TellBio, Inc...announces publication of data from the scientific founders that show a beneficial impact of a novel antibody targeting multiple cadherins on tumor cell dissemination in mouse models of breast and pancreatic cancer....Novel dual-cadherin antibody, 23C6, was initiated on day of inoculation and continued post-resection. Metastasis burden was assessed by CTC enrichment, with the TellDx platform that isolates live cells of both epithelial and mesenchymal lineage, and bioluminescence. Administration of 23C6 demonstrated 100-fold reduction in CTC count in pancreatic cancer model and led to significant metastatic suppression."

Preclinical • Breast Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor